Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)

NCT03274986 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the study is to demonstrate the safety and performance of ACRYSOF IQ extended depth of focus (EDF) intraocular lens (IOL) at Month 6. Depth of focus (DOF) is the amount of focal plane displacement behind a lens that does not degrade the image quality of a distant object. A larger DOF allows sharp images of closer objects and may provide improved vision at intermediate and near distances.

Conditions Studied

Interventions

  • PROCEDURE Cataract surgery
  • DEVICE ACRYSOF® IQ Extended Depth of Focus IOL
  • DEVICE ACRYSOF® IQ Monofocal IOL

Study Locations (11)

Pennsylvania

  • Alcon Investigative Site — Allenwood
  • Alcon Investigative Site — Kingston
  • Alcon Investigative Site — West Mifflin

Florida

  • Alcon Investigative Site — Bradenton
  • Alcon Investigative Site — Sebring

Alabama

  • Alcon Investigative Site — Birmingham

Colorado

  • Alcon Investigative Site — Fort Collins

Georgia

  • Alcon Investigative Site — Gainesville

Illinois

  • Alcon Investigative Site — Rock Island

Ohio

  • Alcon Investigative Site — Cincinnati

South Dakota

  • Alcon Investigative Site — Sioux Falls

Trial Details

FieldValue
Enrollment Target 242 participants
Start Date 2017-10-11
Est. Completion 2018-10-16
Phase NA

Sponsor

Alcon Research

111 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03274986

The ClinicalTrials.gov registry entry for NCT03274986 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 111 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 3 interventions — of which Cataract surgery is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03274986 reports 11 study locations spanning 8 distinct geographic areas — top geographies include Pennsylvania, Florida, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03274986 about?

NCT03274986 is a clinical study titled "A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)". The purpose of the study is to demonstrate the safety and performance of ACRYSOF IQ extended depth of focus (EDF) intraocular lens (IOL) at Month 6. Depth of focus (DOF) is the amount of focal plane displacement behind a lens that does not degrade the image quality of a distant object. A larger DOF ...

What is the current status of trial NCT03274986?

This trial is currently completed. It is a NA study. The enrollment target is 242 participants. The study started on 2017-10-11. Estimated completion is 2018-10-16.

What conditions does trial NCT03274986 study?

This clinical trial studies the following conditions: Cataract. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03274986?

The interventions under investigation include: Cataract surgery (PROCEDURE), ACRYSOF® IQ Extended Depth of Focus IOL (DEVICE), ACRYSOF® IQ Monofocal IOL (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03274986?

This trial is sponsored by Alcon Research, which has 111 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03274986 being conducted?

This trial has 11 study locations across Alabama, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial